Skip to main content Accessibility help
×
Home

Neonatal outcome following buprenorphine maintenance for opiate dependency

  • John Fagan (a1) and Eamon Keenan (a2)

Abstract

Methadone substitution improves maternal and neonatal outcomes. However methadone induced neonatal abstinence syndrome (NAS) is common. Buprenorphine-exposed neonates may be at a lower risk of NAS. Currently in the Republic of Ireland, buprenorphine does not have a special licence for use in pregnancy. We describe here the history and neonatal outcomes of the first Irish woman maintained on buprenorphine during two pregnancies.

Supervised urinanalysis on this mother between and throughout both pregnancies did not reveal any illicit drug use. She delivered two post-term babies of normal birth weight and length. The second infant required treatment for NAS for 21 days with morphine sulphate. Although the use of buprenorphine in pregnancy does not remove the possibility of NAS, neonatal outcomes of buprenorphine-maintained women compares favourably to methadone. As the use of buprenorphine becomes more established in Ireland, the management of buprenorphine-exposed neonates will become more common.

Copyright

Corresponding author

*Correspondence Email: johnc.fagan@hse.ie

References

Hide All
1.Smyth, BP, O'Brien, M. Children Attending Addiction Treatment Services in Dublin 1990-1999. Eur Addict Res 2004; 10: 6874.
2.European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2002 Annual report on the state of the drugs problem in the European Union and Norway. Luxembourg: Office for Official Publications of the European Communities, 2002.
3.Kelly, A, Carvallo, M, Teljeur, C. Prevalence of opiate use in Ireland 2000-2001. A 3-source Capture Recapture study, NACD 2003.
4.Farrell, M, Ward, J, Mattick, Ret al.Methadone maintenance treatment in opiate dependence: a review. BMJ 1994; 309: 9971001.
5.Central Methadone Treatment List, Drug Treatment Central Board, 30-31 Pearse Street, Dublin2.
6. Personal correspondence, Drug Liaison Midwives.
7.Finnegan, LP. Treatment issues for opioid-dependant women during the perinatal period. J Psychoactive Drugs 1991; 23; 191201.
8.Fischer, G. Treatment of opioid dependence in pregnant women. Addiction 2000; 95: 1141–44.
9.Ward, J, Mattick, RP, Hall, W. Methadone maintenance during pregnancy. In: Ward, J, Mattick, RP, Hall, W eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Harwood Academic Publishers 1998.
10.Hulse, G, Milne, E, English, DR, Holman, CDJ. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997; 92: 15711580.
11.Osborn, DA, Cole, MJ, Jeffrey, HE. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Library 2004, issue 3. Oxford: Update Software.
12.Finnegan, LP, Kron, RE, Connaughton, JF, Emich, JP. Assessment and treatment of abstinence in the infant of the drug dependent mother. Int J Clin Pharmacol 1975; 12: 1932.
13.Scully, M, Geoghegan, N, Corcoran, P, Tiernan, M, Keenan, E. Specialized drug liaison midwife services for pregnant opioid dependent women in Dublin, Ireland. J Subst Abuse Treatm 2004; 26: 329335.
14.Dashe, JS, Sheffield, JS, Olscher, DA, Todd, SJ, Jackson, GL, Wendel, GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100(6): 12441249.
15.Stimmel, B, Goldberg, J, Reisman, A, Murphy, RJ, Teets, K. Fetal outcome in narcotic-dependent women: the importance of the type of maternal narcotic used. Am J Drug Alcohol Abuse 19821983; 9(4): 383395.
16.Morrison, CL, Siney, C. A survey of the management of neonatal opiate withdrawal. Eur J Paediatrics 1996; 155: 323326.
17.Johnson, A, Greenough, A, Gerada, C. Maternal drug use and length of neonatal unit stay. Addiction 2002; 98:785789.
18.Coghlan, D, Milner, M, Clarke, Tet al.Neonatal abstinence syndrome, Ir Med J 1999; 92(1): 232–233, 236.
19.Seifert, J, Metzner, C, Paetzold, Wet al.Detoxification of opiate addicts with multiple drug use: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry 2002; 35: 159164.
20.Jones, HE, Johnson, RE, Jasinski, DRet al.Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 110.
21.Fischer, G, Johnson, RE, Eder, Het al.Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000; 95(2): 239244.
22.Lacroix, I, Berrebi, A, Chaumerliac, C, Lapeyre-Mestre, M, Montastruc, JL, Damase-Michel, C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004; 99: 209214.
23.Schindler, SD, Eder, H, Ortner, R, Rohrmeister, K, Langer, M, Fischer, G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003; 98: 103110.
24.Johnson, RE, Jones, HE, Fischer, G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003; 70(2 Suppl): S87S101.
25.Lewis, J, Ranee, MJ, Sanger, DJ. The Pharmacology and abuse potential of buprenorphine: a new antagonistic analgesic. Adv Subt Abuse 1983; 3: 103154.
26.Jones, HE, Martin, PR, Heil, SHet al. Treatment of opioid-dependent Pregnant Women: Clinical and Research Issues. J Subst Abuse Treat in Press (available on-line).
27.Fischer, G, Ortner, R, Rohrmeister, Ket al.Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275281.
28. NIDA – Directors Report – February 2005. www.nida.nih.gov/DirReports/DirRep205/DirectorsReport13.html
29.Abdel-Latif, ME, Pinner, J, Clews, S, Cooke, F, Lui, K, Oei, J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006: 117:1163–69.
30.Auriacombe, M, Loustauneau, A. Medical treatment of the pregnant heroin addict – Review of the literature. In: Pregnancy and drug misuse update 2000. Proceedings: Seminar organised by the Co-operation Group to Combat Drug Abuse and Illicit Trafficking in Drugs (Pompidou Group). Drugs and Addiction. Council of Europe (2000), 3974.
31. Summary of Product Characteristics (SPC) from the IPHA Electronic Medicines Compendium, www.medicines.ie
32.Centre for Substance abuse treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. US Department of Health and Human Services, Rockvill, MD (2005).
33.American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998; 101: 10791085.
34.Choo, RE, Huestis, MA, Schroeder, JR, Shin, AS, Jones, HE. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75: 253260.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed